• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
Home
About Us Contact Us Advertising
Articles
Budgeting Debt Frugal Insurance Investing Making Money Retirement Saving Money
Tips
Money Saving Tips Trash Audit
Make Money Forums Blogs
Create a Blog Control Panel All Entries All Blogs
Tools
Calculators Prescription Drug Coupons Online Savings Accounts Test Your Knowledge Financial Directory Credit Cards

SavingAdvice.com Blog

Bridging the gap between saving money and investing

Subscribe

 

Join Now or Login

  • Home
    • Advertising
  • Tips
    • Money Saving Tips
    • Recycle, Reuse and Repurpose
  • Make Money
  • Credit Score Guide
  • Forums
  • Blogs
    • Create a Blog
  • Tools
  • Financial Basics
    • Back to Basics: Saving Money
    • Back to Basics: Beginners Guide to Retirement
    • Back to Basics: What Every Child Under 10 Should Know About Personal Finance
    • Back to Financial Basics: Investing In Stocks

New Cholesterol Drug Could Cut Strokes and Heart Attacks in Half

September 1, 2014 by Emma Harrison Clark

Study: a new cholesterol drug can cut heart attacks and strokes in half
Good news has come to light for patients in the battle against cholesterol. An experimental trial by Sanofi and Regeneron Pharmaceuticals has proven to cut the number of heart attacks and strokes almost in half. The clinical trial was analysed retrospectively, which means the results are not yet conclusive, but it’s still huge news for millions of patients that suffer from cardio-vascular risk — a disease directly linked to high cholesterol.

The injectable drug is called alirocumab. It targets a protein called PCSK9 and lowers LDL, which can simply be described as the bad cholesterol in our bodies.

Amgen and Pfizer are developing similar drugs which may be on the market as early as next year, netting the companies millions in profit if approved with patients lining up to lower their chances of heart disease. The study has been named Odyssey Long Term, and it’s still underway with 2,341 patients participating.

There will be a requirement for a larger clinical trial to determine efficacy, but Regeneron is reporting consistent results of LDL reduction in the nine large studies it has done this year. The research came to light back in July, but it was only presented on Sunday in Barcelona at the annual meeting of the European Society of Cardiology. Thos participating in the study were less likely to develop serious cardiovascular issues, including heart attacks, cardiac arrest, stroke and chest pain which required hospitalization.

Researchers are understandably optimistic about the trial findings thus far. “To have this result emerge so quickly in this study is very encouraging,” said Jennifer Robinson, the study leader and a cardiologist at the University of Iowa. But the president of the American College of Cardiology, Dr Patrick T. O’Gara, has commented that although the results are “biologically plausible” it’s important to exercise caution due to the retrospective nature of the findings.

The best treatment for cholesterol at present is statin treatment, which is pill based. Should alirocumab be approved, it could be combined with this treatment as a bi-monthly injection for maximum effect. Alirocumab will be especially attractive to those who can’t take statins because they either don’t work properly, or they have negative side effects.

Big pharmaceutical companies will be working hard over the next year to get the drug approved and to market. And with cardiologists calling it “the best news we’ve had for cholesterol management for a decade,” patients can certainly be hopeful.

(Photo courtesy of Okko Pyykko)

Reader Interactions

What did you think about this article?
1 Star2 Stars3 Stars4 Stars5 Stars (7 votes, average: 4.71 out of 5)
Loading...

Comments

    Leave a Reply Cancel reply

    Your email address will not be published. Required fields are marked *

    Primary Sidebar

    • Articles
    • Tips
    • Make Money
    • Credit Score Guide
    • Forums
    • Blogs
    • Tools
    • About
    • Contact

    Subscribe to Our Newsletter
    Your subscription could not be saved. Please try again.
    Your subscription has been successful.
    Copyright © 2025 SavingAdvice.com. All Rights Reserved.
    • Privacy Policy